Clinical trial
Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2…
NCT00165048 · Chinese University of Hong Kong, Other · Unknown status
Key facts
| NCT number | NCT00165048 |
|---|---|
| Title | Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial |
| Official title | Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial |
| Lead sponsor | Chinese University of Hong Kong, Other |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cancer of Stomach |
| Intervention type | Drug |
| Interventions | Vioxx (Rofecoxib) |
| Enrollment | 206 |
| Start date | Oct 1, 2004 |
| First posted | Sep 14, 2005 |
| Last update posted | Dec 9, 2005 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: